– Pharmaceutical Industry Headlines
Most recently updated on April 2nd 2011
Disappointing: Matesanib, experimental lung cancer drug developed by Amgen-Takeda Partnership fails late-phase clinical trials– April 1 2011
Geraldine Ferraro’s Death highlights issue of high costs for cancer drugs—March 31 2011
ALARMING: Hospitals all over US reporting that drug shortages are the “new normal” – Tennessee –Virginia
Stealth and Wealth, not Mental Health, driving Psychiatric Pharma—March 31 2011
Well running dry on Big Pharma’s Neuroscience Pipelines—March 31 2011
An Ounce of Prevention is Worth a Pound of Cure—FDA and WHO target side effects and ADRs before they occur—March 31 2011
Pharma Strategy Moves from Sales Reps to Opinion Leadership– March 31 2011
MAJOR HEADLINE: Big Pharma’s Influence on Doctors
***More on this: 1/4 Practitioners Refuse to see Pharm Sales Reps
How Big Pharma Influences Private Practice—March 28 2011
Expose on the Pharmaceutical Industry and Marketing – March 28
——————————————————————–
MERGE: Proctor-Gamble + Teva Teaming up spells Big News on Horizon for OTC Meds—March 26 2011
BUSINESS: $220M deal – PerkinElmer Buys NC Pharma IT Company ArtusLabs—March 26 2011
–LEGAL 2: Minnesota Lawsuit has Potential to rain on Generic’s Parade, and be a game changer for generic medications and warning labels—March 25 2011
Leaked Memo from Canada’s Industry Minister on making the country less hostile to Pharmaceutical R&D– March 26 2011
Ruckus in Canada: Liberals on the Out try to Enact Legislation that would annihilate Pharma’s ability to compete – March 26 2011
HCPC Meeting Targets Discussion of Patient Adherence– March 24 2011
Access Pharmaceuticals Appoints Anthony Mottola as new VP of Managed Care—March 23 2011
Analysts think Wal-Mart’s $4 generics is a “prescription” for $6b in savings—March 23 2011
Zicam Finds Itself on the Wrong End of the Supreme Court—March 23 2011
*Accenture’s Global Managing Director’s Views on shaping the future of Pharmaceutical R&D—March 23 2011
*Pharma begins reacting to SCM—Supply Chain Management: Britain’s developments may serve as predictors of American industry trends.– March 23 2011
*Most recent, 10 Biggest Drug discoveries worth $50B by 2015—Mar 23
*Patient Advocacy Groups and their growing influence challenges Big Pharma paradigms—strategies to adapt to a changing reality– March 23 2011
*Who’s Going to Pay for Future Drug Development: Part One—March 22 2011
answer that question—and explores whether or not Big Pharma can step in to facilitate—March 21 2011
*Is electronic file reconciliation the answer to the FDA’s lousy track record the last couple of years? What? The FDA has a lousy track record? – March 21 2011
In an otherwise sour economy, FDA Consulting services boom in Orlando, FL – March 17 2011
What a Stanford Study found out about the real cost of Pharmaceutical R&D
Merck and Schering-Plough Fight over Profits from Arthritis Drug Remicade
**MAJOR HEADLINE: ***
————————————————————